PEG-RLI: A Long-Acting IL-15 Agonist That Produces Massive Levels of CD8+ and CD44hiCD8+ Cells for Cancer Immunotherapy
Open Access
- 15 July 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 863
Abstract
Background/Objectives: Interleukin-15 (IL-15) is a promising immunotherapeutic cytokine, but its short half-life limits clinical utility. We developed a stable PEGylated receptor-linker IL-15 agonist (PEG-RLI) to improve pharmacokinetic properties while preserving biological activity and antitumor efficacy. Methods: PEG-RLI was synthesized by site-specific N-terminal conjugation of a 40 kDa methoxy polyethylene glycol (MeOPEG) to RLI. The conjugate was characterized for purity and receptor agonism. Pharmacokinetics were evaluated in mice, and pharmacodynamic effects on NK cells and CD8+ T cell subsets were assessed. Antitumor activity was tested in CT26 tumor-bearing mice alone and in combination with anti-PD-1 therapy. Results: PEGylation preserved RLI agonistic activity and extended its mouse half-life from approximately 3 h to approximately 15 h. PEG-RLI induced robust expansion of NK cells and CD8+ T cells, with preferential enrichment of CD8+ T cells and CD44hiCD8+ T cells. In CT26 solid tumors, PEG-RLI enhanced the antitumor efficacy of anti-PD-1 treatment. Conclusions: Stable PEGylation improved the pharmacokinetic profile of RLI while maintaining potent immunostimulatory activity. PEG-RLI preferentially expanded CD8+ T cells and showed promising efficacy with immune checkpoint blockade, supporting further development as a differentiated IL-15-based immunotherapeutic.Keywords
This publication has 56 references indexed in Scilit:
- Long-Acting, Longer-Acting, and Ultralong-Acting Antiobesity PeptidesJournal of Medicinal Chemistry, 2025
- CD8+ T cells in the cancer-immunity cycleImmunity, 2023
- To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternativesAdvanced Drug Delivery Reviews, 2021
- Approach for Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue UptakeBioconjugate Chemistry, 2016
- IL-2 and IL-15 signaling complexes: different but the sameNature Immunology, 2012
- Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15Nature Immunology, 2012
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterizationCytokine, 2011
- PS1-57 Different dynamics of IL-15R activation following IL-15 cis- or trans-presentationCytokine, 2010
- Trans-presentation: A novel mechanism regulating IL-15 delivery and responsesImmunology Letters, 2010
- Identification and cloning of a novel IL‐15 binding protein that is structurally related to the alpha chain of the IL‐2 receptor.The EMBO Journal, 1995